ArticlePhysiological research2025
Rehmannioside A Attenuates Inflammation via Inactivation of the p-p65 NF-?B and p-p38 MAPK Signaling in Abdominal Infection-Induced Acute Kidney Injury.
Article in Physiological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Septic acute kidney injury (AKI) is the most common type of acute kidney failure observed in hospitalized patients, with inflammation playing a central role in its pathogenesis. The study aimed to investigate the influence of Rehmannioside A (Re A), a natural ingredient from the traditional Chinese herb Rehmanniae radix, on renal dysfunction and inflammation in septic AKI. Peripheral venous blood specimens were obtained from septic patients with and without AKI for comparing their clinical profiles. A rat model of sepsis was established through cecal ligation and puncture (CLP) surgery, followed by intraperitoneal injections of Re A. Biochemical analysis was performed to measure concentrations of kidney function indicators including blood urea nitrogen (BUN) and serum creatinine (Scr). Structural changes in kidney samples were evaluated by hematoxylin-eosin staining. Colony forming units of bacteria were counted in blood and renal samples of rats. Enzyme-linked immunosorbent assay was performed to measure serum and renal levels of proinflammatory cytokines (TNF? and IL-1?). Protein levels of factors related to MAPK and NF-?B pathways were quantified by western blotting. AKI patients showed increases in sepsis-related organ failure assessment (SOFA) score, BUN, Scr, TNF? and IL-1? levels compared to non-AKI patients. Re A improved the survival rate of CLP model rats and reversed CLP-induced increase in BUN and Scr levels. Pathological changes including renal tubular swelling and luminal narrowing induced by CLP were effectively ameliorated by Re A. In addition, Re A reduced bacterial load and proinflammatory cytokine levels in both blood and renal samples. As to the mechanism, Re A inactivated the phosphorylated levels of p38 MAPK and p65 NF-?B rat kidney samples. Re A plays renal-protective and anti-inflammatory properties in the rat model of septic AKI by inhibiting the activation of p38 MAPK and p65 NF-?B signaling. Keywords Acute kidney injury " Inflammation " Rehmannioside A " Renal dysfunction " Sepsis.
Indexed as
Identifiers
41406481PMC12721818What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.